Market capitalization | $1.05b |
Enterprise Value | $1.04b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 35.20 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-46.13m |
Free Cash Flow (TTM) Free Cash Flow | $-35.54m |
Cash position | $26.20m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Pulse Biosciences, Inc.:
1 Analyst has issued a forecast Pulse Biosciences, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.14 -1.14 |
90%
90%
|
|
EBITDA | -45 -45 |
1%
1%
|
EBIT (Operating Income) EBIT | -46 -46 |
1%
1%
|
Net Profit | -44 -44 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Head office | United States |
CEO | Burke Barrett |
Employees | 56 |
Founded | 2014 |
Website | www.pulsebiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.